{"id":45016,"date":"2023-11-10T10:32:11","date_gmt":"2023-11-10T08:32:11","guid":{"rendered":"https:\/\/www.ipsen.com\/?p=45016"},"modified":"2024-09-23T15:00:58","modified_gmt":"2024-09-23T13:00:58","slug":"examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report","status":"publish","type":"post","link":"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/","title":{"rendered":"Examining the European Pharma legislation: EFPIA publishes the Dolon Report"},"content":{"rendered":"\n<p>The European Federation of Pharmaceutical Industries and Associations (EFPIA) has commissioned Dolon to develop a report to assess the impact of the proposed European Commission pharma legislation. The Dolon Report, published on 6 November, has projected that the proposed legislation will negatively impact research and development in the pharmaceutical industry in Europe, potentially impacting the lives of patients around the world. \u00a0Below are some of the projected outcomes if the legislation is adopted.<\/p>\n\n\n\n<figure class=\"wp-block-gallery has-nested-images columns-default is-cropped wp-block-gallery-1 is-layout-flex wp-block-gallery-is-layout-flex\">\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"509\" height=\"504\" data-id=\"45026\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10102815\/Image1-1.png\" alt=\"\" class=\"wp-image-45026\" srcset=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10102815\/Image1-1.png 509w, https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10102815\/Image1-1-300x297.png 300w, https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10102815\/Image1-1-150x150.png 150w\" sizes=\"(max-width: 509px) 100vw, 509px\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-large\"><img decoding=\"async\" width=\"331\" height=\"330\" data-id=\"45025\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10102815\/Image2-1.png\" alt=\"\" class=\"wp-image-45025\" srcset=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10102815\/Image2-1.png 331w, https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10102815\/Image2-1-300x300.png 300w, https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10102815\/Image2-1-150x150.png 150w\" sizes=\"(max-width: 331px) 100vw, 331px\" \/><\/figure>\n\n\n\n<figure class=\"wp-block-image size-full\"><img decoding=\"async\" width=\"337\" height=\"342\" data-id=\"45023\" src=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10102815\/Image3-1.png\" alt=\"\" class=\"wp-image-45023\" srcset=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10102815\/Image3-1.png 337w, https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10102815\/Image3-1-296x300.png 296w, https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10102815\/Image3-1-148x150.png 148w\" sizes=\"(max-width: 337px) 100vw, 337px\" \/><\/figure>\n<\/figure>\n\n\n\n<p>Find out more about the potential impact: read EFPIA\u2019s press release <a href=\"https:\/\/www.efpia.eu\/news-events\/the-efpia-view\/statements-press-releases\/germany-belgium-and-france-among-those-hit-hardest-as-commission-s-pharma-legislation-proposals-risk-europe-losing-a-third-of-its-share-of-global-rd-by-2040\/\"><strong>here<\/strong><\/a> and the full report <a href=\"https:\/\/www.efpia.eu\/media\/msadqxbf\/revision-of-the-general-pharmaceutical-legislation-gpl-impact-assessment.pdf\"><strong>here<\/strong><\/a>.<\/p>\n","protected":false},"excerpt":{"rendered":"<p>The European Federation of Pharmaceutical Industries and Associations (EFPIA) has commissioned Dolon to develop a report to assess the impact<\/p>\n","protected":false},"author":11,"featured_media":45029,"comment_status":"closed","ping_status":"open","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[121],"tags":[],"class_list":["post-45016","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-general","entry"],"acf":[],"yoast_head":"<!-- This site is optimized with the Yoast SEO plugin v22.5 - https:\/\/yoast.com\/wordpress\/plugins\/seo\/ -->\n<title>Examining the European Pharma Legislation - Efpia Publishes the Dolon Report<\/title>\n<meta name=\"description\" content=\"Learn about the Dolon report published by Efpia examining the European pharma legislation and its impact on the industry.\" \/>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/\" \/>\n<meta property=\"og:locale\" content=\"en_US\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Examining the European Pharma Legislation - Efpia Publishes the Dolon Report\" \/>\n<meta property=\"og:description\" content=\"Learn about the Dolon report published by Efpia examining the European pharma legislation and its impact on the industry.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:published_time\" content=\"2023-11-10T08:32:11+00:00\" \/>\n<meta property=\"article:modified_time\" content=\"2024-09-23T13:00:58+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10103141\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg\" \/>\n\t<meta property=\"og:image:width\" content=\"1082\" \/>\n\t<meta property=\"og:image:height\" content=\"620\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"author\" content=\"heloisedetouchet\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:creator\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Written by\" \/>\n\t<meta name=\"twitter:data1\" content=\"heloisedetouchet\" \/>\n\t<meta name=\"twitter:label2\" content=\"Est. reading time\" \/>\n\t<meta name=\"twitter:data2\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"Article\",\"@id\":\"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/\"},\"author\":{\"name\":\"heloisedetouchet\",\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/person\/bc60024b750ef600f500463cf86905c4\"},\"headline\":\"Examining the European Pharma legislation: EFPIA publishes the Dolon Report\",\"datePublished\":\"2023-11-10T08:32:11+00:00\",\"dateModified\":\"2024-09-23T13:00:58+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/\"},\"wordCount\":100,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10103141\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg\",\"articleSection\":[\"General\"],\"inLanguage\":\"en-US\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/\",\"url\":\"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/\",\"name\":\"Examining the European Pharma Legislation - Efpia Publishes the Dolon Report\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10103141\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg\",\"datePublished\":\"2023-11-10T08:32:11+00:00\",\"dateModified\":\"2024-09-23T13:00:58+00:00\",\"description\":\"Learn about the Dolon report published by Efpia examining the European pharma legislation and its impact on the industry.\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/#breadcrumb\"},\"inLanguage\":\"en-US\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/#primaryimage\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10103141\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10103141\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg\",\"width\":1082,\"height\":620},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Examining the European Pharma legislation: EFPIA publishes the Dolon Report\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/#website\",\"url\":\"https:\/\/www.ipsen.com\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"en-US\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/person\/bc60024b750ef600f500463cf86905c4\",\"name\":\"heloisedetouchet\",\"image\":{\"@type\":\"ImageObject\",\"inLanguage\":\"en-US\",\"@id\":\"https:\/\/www.ipsen.com\/#\/schema\/person\/image\/\",\"url\":\"https:\/\/secure.gravatar.com\/avatar\/3953d070f3f9f21285865eb069e19b28?s=96&d=mm&r=g\",\"contentUrl\":\"https:\/\/secure.gravatar.com\/avatar\/3953d070f3f9f21285865eb069e19b28?s=96&d=mm&r=g\",\"caption\":\"heloisedetouchet\"}}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Examining the European Pharma Legislation - Efpia Publishes the Dolon Report","description":"Learn about the Dolon report published by Efpia examining the European pharma legislation and its impact on the industry.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/","og_locale":"en_US","og_type":"article","og_title":"Examining the European Pharma Legislation - Efpia Publishes the Dolon Report","og_description":"Learn about the Dolon report published by Efpia examining the European pharma legislation and its impact on the industry.","og_url":"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/","og_site_name":"Global","article_published_time":"2023-11-10T08:32:11+00:00","article_modified_time":"2024-09-23T13:00:58+00:00","og_image":[{"width":1082,"height":620,"url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10103141\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg","type":"image\/jpeg"}],"author":"heloisedetouchet","twitter_card":"summary_large_image","twitter_creator":"@ipsengroup","twitter_site":"@ipsengroup","twitter_misc":{"Written by":"heloisedetouchet","Est. reading time":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"Article","@id":"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/"},"author":{"name":"heloisedetouchet","@id":"https:\/\/www.ipsen.com\/#\/schema\/person\/bc60024b750ef600f500463cf86905c4"},"headline":"Examining the European Pharma legislation: EFPIA publishes the Dolon Report","datePublished":"2023-11-10T08:32:11+00:00","dateModified":"2024-09-23T13:00:58+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/"},"wordCount":100,"publisher":{"@id":"https:\/\/www.ipsen.com\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10103141\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg","articleSection":["General"],"inLanguage":"en-US"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/","url":"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/","name":"Examining the European Pharma Legislation - Efpia Publishes the Dolon Report","isPartOf":{"@id":"https:\/\/www.ipsen.com\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10103141\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg","datePublished":"2023-11-10T08:32:11+00:00","dateModified":"2024-09-23T13:00:58+00:00","description":"Learn about the Dolon report published by Efpia examining the European pharma legislation and its impact on the industry.","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/#breadcrumb"},"inLanguage":"en-US","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/"]}]},{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/#primaryimage","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10103141\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/11\/10103141\/Thumbnail_EFPIA_Dolon-Report_1082x620pix.jpg","width":1082,"height":620},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/general\/examining-the-european-pharma-legislation-efpia-publishes-the-dolon-report\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/"},{"@type":"ListItem","position":2,"name":"Examining the European Pharma legislation: EFPIA publishes the Dolon Report"}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/#website","url":"https:\/\/www.ipsen.com\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"en-US"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/","logo":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ipsen.com\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":"https:\/\/www.ipsen.com\/#\/schema\/person\/bc60024b750ef600f500463cf86905c4","name":"heloisedetouchet","image":{"@type":"ImageObject","inLanguage":"en-US","@id":"https:\/\/www.ipsen.com\/#\/schema\/person\/image\/","url":"https:\/\/secure.gravatar.com\/avatar\/3953d070f3f9f21285865eb069e19b28?s=96&d=mm&r=g","contentUrl":"https:\/\/secure.gravatar.com\/avatar\/3953d070f3f9f21285865eb069e19b28?s=96&d=mm&r=g","caption":"heloisedetouchet"}}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/posts\/45016","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/users\/11"}],"replies":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/comments?post=45016"}],"version-history":[{"count":3,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/posts\/45016\/revisions"}],"predecessor-version":[{"id":68302,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/posts\/45016\/revisions\/68302"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/media\/45029"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/media?parent=45016"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/categories?post=45016"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/wp-json\/wp\/v2\/tags?post=45016"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}